Year: 2025
Type: article
Study design: Observational Study
Abstract: Background: Since the introduction of immune checkpoint inhibition (ICI), the outcome of advanced cutaneous melanoma (CM) has improved substantially. Yet, for mucosal melanoma (MM), the prognosis in advanced settings remains dire, with reported median progression-free survival (mPFS) and median overall survival (mOS) of 4 months and 19 months, respectively (1). Prospective data from randomized clinical trials remain scarce due to the rarity of this melanoma subtype, highlighting the importance of retrospective real-world data.
Source: EJC Skin Cancer
Authors: K.G. S. Frey, T. Amaral, M.-L. Rasch, A. Meiwes, L. Flatz, L. Nanz, U. Leiter-Stöppke
Institutions: Universitätsklinikum Tübingen, Kantonsspital St. Gallen
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,340
OpenAlex ID: W4409145127